Merck Sharp + Dohme Corp.

Sgx Pharmaceuticals, Inc.

Richard Pracitto

John Howard Hutchinson

Joseph P Vacca

Jean-Michel Andre Vernier

John S Wai

Steven P Govek

Brian Walter Eastman

Gavin C Hirst

Theodore M Kamenecka

Ruo W Steensma

Linda S Payne

Chixu Chen

Andreas Gosberg

Stephanie Hopkins

Stefan N Gradl

Richard C A Isaacs

Khanh Thi Tuong Nguyen

Paul E Sprengeler

Wei Han

The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

Fused ring heterocycle kinase modulators

The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Benzazole potentiators of metabotropic glutamate receptors

Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

HIV integrase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Richard Pracitto